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Abstract  The prognosis of superficial bladder cancer in 
terms of recurrence and disease progression is related to 
bladder tumor multiplicity and the presence of concomi- 
tant "plane" tumors such as high-grade dysplasia nd car- 
cinoma in situ. This study in 33 patients aimed to demon- 
strate the role of fluorescence cystoscopy in transurethral 
resection of superficial bladder cancer. The method is 
based on the detection of protoporphyrin-IX-induced flu-
orescence in urothelial cancer cells by topical administra- 
tion of 5-aminolevulinic a id. The sensitivity and the spec- 
ificity of this procedure on apparently normal mucosa in 
superficial bladder cancer are estimated to be 82.9% and 
81.3%, respectively. Thus, fluorescence cytoscopy is a 
simple and reliable method for mapping the bladder 
mucosa, especially in the case of multifocal bladder dis- 
ease, and it facilitates the screening of occult dysplasia. 
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Introduction 
In superficial bladder transitional cell carcinoma, tumor 
multiplicity and concomitant urothelial atypia are indica- 
tors of a poor disease prognosis [1, 2]. High-grade dyspla- 
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sia or carcinoma in situ point to a higher isk of recurrence 
or progression [I, 3]. Occasionally, reddish and mossy 
spots of the bladder mucosa allow the localization by 
biopsy of these foci of dysplasia, but mostly no specific 
changes of the bladder wall can be recognized by white 
light cystoscopy [4]. 
Although its accuracy is highly variable, urinary blad- 
der cytology as a routine test in the early detection of blad- 
der cancer and in the patient monitoring after treatment is
well established, but does not enable concomitant urothe- 
lial atypia at the time of the first bladder tumor resection 
to be discovered. Moreover, the usefulness of random 
biopsies from normal-looking mucosa has recently been 
seriously questioned [5]. Therefore, as for epithelial can- 
cers of other organs such as the oesophagus or the uterine 
cervix, there is a need to localize urothelial atypia during 
the endoscopic exploration. 
Simple methods uch as mucosal staining with methyl- 
ene blue have failed due to lack of sensitivity and speci- 
ficity [6]. Fluorescence studies correlated with histology 
on cystectomy specimens after intravenous injection ofhe- 
matoporphyrin derivatives have demonstrated the possible 
role of a photodynamic method for detecting and localiz- 
ing dysplasia nd carcinoma in situ in bladder cancer [7]. 
However, the sophisticated equipment needed to obtain 
good images, the lack of selectivity of the photosensitizer 
and the risk of skin photosensitization have limited its ap- 
plication for clinical routine practice in urology. Recently, 
the high fluorescence ontrast and intensity observed when 
treating cutaneous in situ tumors by photodynamic therapy 
using the endogenous photosensitizer p otoporphyrin IX
(PpIX), induced by the topical application of 5-amino- 
levulinic acid (ALA), has suggested the same approach 
to be suitable for detection and treatment of epithelial tu- 
mors of other organs, such as the oesophagus and the 
bladder [8]. The first clinical reports on the photodetection 
of early transitional cell carcinoma by light-induced fluo- 
rescence of PpIX following topical administration ofALA 
[9, 11] stimulated interest in this new method of mapping 
the bladder mucosa in search of dysplasia or carcinoma in 
situ. 
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By comparison to the first system of bladder wall  
i l lumination with a krypton ion laser, the new light 
source, a xenon arc lamp, considerably simplif ies the 
procedure by enabling the investigator to examine the 
bladder wall in real time without the necessity for an aux- 
i l iary device. This study presents our experience with this 
new system and attempts to assess the accuracy of the 
method in the detection of high-grade dysplasia nd carci- 
noma in situ. 
Material and method 
Fifty milliliters of a 3% solution of ALA, buffered with 5 ml phos- 
phate-buffered saline (PBS) and adjusted to a pH of 5.3 with 7 ml 
sodium hydroxide (1 N), were instilled into the bladder through a 
16-French Foley catheter about 6 h before photodetection. Patients 
were asked to keep the catheter closed for 4 h to optimize the 
exposure of the bladder wall to the photosensitizing solution. The 
light source was a filtered xenon arc lamp which produced either 
white light for conventional cystoscopy or blue light with a 
wavelength range of 380-450 nm to excite the sensitized bladder mu- 
cosa. A foot pedal was used to switch from white to blue light 
and vice versa when necessary. The power of the fluorescence exci- 
tation light at the end of the cystoscope ranged between 150 and 
480 mW, giving under normal conditions of use a power density of 
2 65 mW/cm . The white light, the blue excitation light and the result- 
ing tissue fluorescence were transmitted through the optical fiber 
bundle of a Storz cystoscope or resectoscope. Two optics of 0 ° and 
of 30 °, suitable for either a cystoscope or resectoscope sheath, were 
specially configured to optimize the light transmission. As the PpIX 
emission peak was 635 nm, a long-pass filter (X>490 nm) was 
adapted to the ocular piece of the cystoscope to transmit he red 
and cut out most of the blue-reflected xcitation light. Thus, the flu- 
orescent spots appeared red, whereas the non-fluorescent mucosa 
stayed green. The somewhat darker bladder wall vessels facilitated 
the positioning of the cytoscope during the operation. 
Starting in January t995, 33 bladder examinations were per- 
formed in 31 patients, 23 male patients and 8 female patients (two 
patients had two successive operations). Mean age was 66.1, rang- 
ing from 44 to 84 years. Eleven patients were operated on for 
the first time, 6 for the second time and 16 for the third time or 
more. Topical chemotherapy or immunotherapy with bacille Cal- 
mette-Gu6rin (BCG) was added to the previous urgical treatment in
19 patients. Bladder urinary cytological examination was regularly 
performed when the catheter was introduced for the ALA instilla- 
tion. 
The operation always started with a careful bladder inspection 
under white light in order to note the presence, number and location 
of all the visible tumors and suspicions areas. To evaluate the 
sensitivity and the specificity of the method in patients with bladder 
tumors, a four-quadrant random biopsy of the normal bladder 
mucosa was performed for each patient as follows: the randomly des- 
ignated spot of normal mucosa under white light was excited under 
blue light to determine the fluorescence r sponse and then immedi- 
ately sampled by forceps for biopsy. A total of 132 random biopsies 
were obtained in this way, 51 in fluorescent areas and 81 in non- 
fluorescent areas. All other fluorescent areas on an apparently nor- 
mal or slightly irregular mucosa under white light were also biop- 
sled and sent for analysis. The transurethral resection of significant 
tumors was generally performed under fluorescence, xcept in the 
case of major bleeding. Papillary and nonpapillary urothelial carci- 
nomas were graded and staged according to the WHO 1973 classi- 
fied [12] and the IUCC/AJC-1992 system [13], respectively. Flat 
intraepithelial neoplastic lesions were graded according to the crite- 
ria of Nagy et al. [14], and classified as grade 1 (mild dysplasia), 
grade 2 (moderate dysplasia), grade 3 (marked ysplasia) and in si- 
tu carcinoma. 
Results 
No systemic or local side effects fol lowing ALA bladder 
insti l lation either before or after the photodetect ion proce- 
dure were noted. Except for one pTaG1 tumor, all papil-  
lary tumors visible on white l ight cystoscopy were fluo- 
rescent. The correlations between the f luorescence find- 
ings and the presence or absence of cancer cells for the 
132 random biopsies on apparently normal mucosa are 
shown in Table 1. The predict ive value of a posit ive fluo- 
rescence corresponding to a tumor is estimated at 66.6% 
(34/51), and the predict ive value of a negative f luorescence 
corresponding to benign tissue at 91.3 % (74/81). The sen- 
sitivity of this photodetect ion method in superficial blad- 
der cancer can be estimated at 82.9% (34/41) and the spec- 
if icity at 81.3% (74/91). 
In 22/33 patients, 66.6% of our col lective, 47 tumors 
were detected by the f luorescence (Table 2). Seven of these 
22 patients (31.8%) had grade 3 dysplasia or carcinoma in 
situ (CIS). Table 3 shows the correlations between cytol- 
ogy, white l ight cystoscopy and f luorescence f indings 
for each patient. The f luorescence method detected addi- 
t ional urothelial atypia, invisible under white light, in 
12/14 patients (85%) with mult iple tumors and in 5/12 pa- 
tients (41%) with a single tumor. In contrast to the 
f luorescence cytoscopy, urinary cytology was not real ly 
helpful in patients with macroscopic tumors. For patients 
previously operated on for a superficial bladder cancer, 
who presented no specific lesion on white l ight cystoscopy, 
f luorescence cystoscopy conf irmed the absence of neo- 
plastic lesions in three and detected urothelial atypia or 
even a small tumor in four of them. In these cases, urinary 
cytology could only give an indication of the presence or 
absence of cancerous cells, whereas f luorescence cytos- 
copy precisely del ineated the number of carcinomatous 
spots. 
Table 1 Correlation between fluorescence findings and histopath- 
ological diagnosis for the 132 random biopsies on apparently nor- 
mal mucosa in superficial bladder cancer 
Positive Negative Total 
histology histology 
Positive fluorescence 34 17 51 
Negative fluorescence 7 74 81 
41 91 132 
Table 2 Diagnosis distribution of the 47 tumors invisible by 
white light cystoscopy and detected by fluorescence in 22/33 
patients 
"Flat" intraepithelial tumors 41 Papillary tumors 6 
Grade 1 dysplasia 12 pTaG1 2 
Grade 2 dysplasia 15 pTaG2 3 
Grade 3 dysplasia 3 pT1G3 1 
Carcinoma in situ 11 
Table 3 Correlation between cytology, white light cystoscopy (CUS) and fluorescence findings 
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Cytology White light CUS a Diagnosis 
TaG1 TaG2 T1G2 T1G3 
Fluorescence CUS b 
Dys G1-2 Dys G3-CIS TaG2 
Correct 6 x Multiple tumors 14 3 7 1 3 
Correct 5 x Unique tumor 12 6 5 0 1 
Correct 5 x No specific lesion 7 No tumor 
9 3 0 
3 2 0 
1 1 2 
a Except one pTaGl tumor, all papillary tumors, visible by white light cystoscopy, were fluorescent 
b Additional tumors invisible under white light and detected by fluorescence 
Discussion 
In the Canton of Vaud in Switzerland, the incidence of 
superficial bladder cancer is around 18.6/100 00 per year 
in male patients and 4.2/100000 per year in female pa- 
tients, which represents a ratio of  4:1 [15]. The individual 
risk of cancer progression, reflecting the natural history of 
the disease, varies from 4 to 45% [16]. Moreover, in the 
year following the first treatment, superficial bladder can- 
cer tends to recur in a proportion up to 70%; and 10-20% 
of recurrences on the site of the initial tumor grow from 
carcinomatous foci left during the first operation [17]. I f  
the characterization of dysplastic changes in the urothe- 
lium is important in the evaluation of the disease progno- 
sis and the risk of recurrence, the surgical treatment of all 
exophytic and "flat" tumors during the first operation is 
mandatory. 
So far no reliable method has been available to deter- 
mine the cancer cells in delineating the tumor basis and 
screening urothelial atypia. PpIX-induced fluorescence de- 
tection of urothelial cancer cells by topical administration 
of  ALA is a simple and harmless method for this. No lo- 
cal or systemic reaction was noted after ALA  bladder in- 
stillation or illumination with the xenon blue light. The cor- 
relation between the fluorescence tissue response and the 
histopathological diagnosis on normal mucosa in superfi- 
cial bladder cancer establishes that a fluorescent spot cor- 
responds to a carcinoma in about two out of three cases 
and above all that a nonfluorescent spot corresponds to be- 
nign tissue in nine out of ten cases. Undoubtedly, fluores- 
cence cystoscopy aids in the biopsy of the urothelium at 
the right place in bladder cancer. The electrocoagulation 
of false-positive fluorescent areas, due to inflammatory or 
hyperplastic ells, does not harm the bladder with normal 
compliance. 
The sensitivity and the specificity of  the procedure on 
apparently normal mucosa in patients with superficial 
bladder cancer is estimated at 82.9% and 81.3%, respec- 
tively. Calculated on a per patient basis it has been esti- 
mated at 94.2% by the Munich group [10]. Following the 
same approach in our collective, bladder biopsies revealed 
dyspastic urothelial changes or CIS in 23 patients, among 
whom 22 had a positive fluorescence. Thus, our per pa- 
tient estimated sensitivity is near 95.6%, an equivalent 
value to the previous estimation. 
Fluorescence cystoscopy constitutes a previous aid to 
white light cystoscopy. It is a simple and a reliable method 
in mapping the mucosa in bladder cancer. It facilitates the 
delineation of tumors and the screening of occult dysplas- 
tic changes, especially in multiple papillary bladder dis- 
ease. In addition, it appears very useful in monitoring the 
patients after treatment. 
Subsequent studies will be needed to assess whether the 
optimal transurethal bladder esection obtained with fluo- 
rescence cytoscopy contributes to a reduction of the risk 
of recurrence in superficial bladder cancer. 
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